{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:58:06Z","timestamp":1781643486785,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>This article reviews the evidence for cardiovascular and renal risk reduction with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in type 2 diabetes mellitus (T2DM), based on randomized controlled trials, including emerging oral agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Injectable GLP-1 RAs have consistently demonstrated reductions in major adverse cardiovascular events (MACE) and clinically relevant kidney outcomes, establishing their role in cardiorenal risk reduction. Oral semaglutide, the first approved oral GLP-1 RA, met criteria for cardiovascular non-inferiority in PIONEER 6 among patients with T2DM at high cardiovascular risk. The SOUL trial (oral semaglutide) subsequently demonstrated superiority for MACE reduction versus placebo in patients with established cardiovascular disease or multiple risk factors, with benefit driven largely by fewer nonfatal myocardial infarctions. However, oral semaglutide did not significantly reduce major kidney outcomes. Orforglipron, an investigational non-peptide oral GLP-1 RA with once-daily, food-independent dosing, has shown robust glycemic and weight-loss efficacy in phase 3 trials, though cardiovascular and renal outcome data are pending.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Oral semaglutide has demonstrated cardiovascular benefit, but evidence supporting prevention of renal outcomes with oral GLP-1 RAs remains limited. Injectable GLP-1 RAs currently have the strongest evidence base for cardiorenal risk reduction, and ongoing outcome trials will clarify whether newer oral agents can close this gap.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11886-026-02357-5","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T09:16:24Z","timestamp":1774257384000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Oral Glucagon-Like Peptide-1 Receptor Agonists for Preventing Cardiorenal Complications"],"prefix":"10.1007","volume":"28","author":[{"given":"Victoria","family":"Odeleye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swotantra","family":"Gautam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Shannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Matthew","family":"Bibb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"McClure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timir K.","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"issue":"3","key":"2357_CR1","doi-asserted-by":"publisher","first-page":"101429","DOI":"10.1016\/j.diabet.2023.101429","volume":"49","author":"PH Ducluzeau","year":"2023","unstructured":"Ducluzeau PH, et al. Prevalence and incidence of cardiovascular and renal diseases in type 1 compared with type 2 diabetes: A nationwide French observational study of hospitalized patients. Diabetes Metab. 2023;49(3):101429.","journal-title":"Diabetes Metab"},{"issue":"15","key":"2357_CR2","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1016\/j.cell.2024.06.029","volume":"187","author":"ED Abel","year":"2024","unstructured":"Abel ED, et al. Diabetes mellitus-Progress and opportunities in the evolving epidemic. Cell. 2024;187(15):3789\u2013820.","journal-title":"Cell"},{"issue":"12","key":"2357_CR3","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1016\/j.ekir.2022.09.018","volume":"7","author":"RZ Alicic","year":"2022","unstructured":"Alicic RZ, et al. Use of Glucose-Lowering Agents in Diabetes and CKD. Kidney Int Rep. 2022;7(12):2589\u2013607.","journal-title":"Kidney Int Rep"},{"issue":"4","key":"2357_CR4","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/HCO.0000000000000955","volume":"37","author":"AC Mares","year":"2022","unstructured":"Mares AC, Chatterjee S, Mukherjee D. Semaglutide for weight loss and cardiometabolic risk reduction in overweight\/obesity. Curr Opin Cardiol. 2022;37(4):350\u20135.","journal-title":"Curr Opin Cardiol"},{"issue":"4","key":"2357_CR5","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","volume":"27","author":"DJ Drucker","year":"2018","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740\u201356.","journal-title":"Cell Metab"},{"issue":"4","key":"2357_CR6","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"19","key":"2357_CR7","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"issue":"10193","key":"2357_CR8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121\u201330.","journal-title":"Lancet"},{"issue":"10","key":"2357_CR9","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","volume":"385","author":"HC Gerstein","year":"2021","unstructured":"Gerstein HC, et al. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. N Engl J Med. 2021;385(10):896\u2013907.","journal-title":"N Engl J Med"},{"issue":"10157","key":"2357_CR10","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519\u201329.","journal-title":"Lancet"},{"key":"2357_CR11","doi-asserted-by":"publisher","DOI":"10.2174\/011871529X421551250801194823","author":"E Luna-Ceron","year":"2025","unstructured":"Luna-Ceron E, Kattamuri L, Duvvuru SR, Mukherjee D. Oral semaglutide: a step forward in cardiovascular risk management for type 2 diabetes. Cardiovasc Hematol Disord Drug Targets. 2025. https:\/\/doi.org\/10.2174\/011871529X421551250801194823.","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"issue":"2","key":"2357_CR12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/scipharm93020026","volume":"93","author":"HI Sald\u00edvar-Cer\u00f3n","year":"2025","unstructured":"Sald\u00edvar-Cer\u00f3n HI, et al. Oral Small-Molecule GLP-1 Receptor Agonists: Mechanistic Insights and Emerging Therapeutic Strategies. Sci Pharm. 2025;93(2):26.","journal-title":"Sci Pharm"},{"issue":"9","key":"2357_CR13","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019;381(9):841\u201351.","journal-title":"N Engl J Med"},{"issue":"20","key":"2357_CR14","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","volume":"392","author":"DK McGuire","year":"2025","unstructured":"McGuire DK, et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med. 2025;392(20):2001\u201312.","journal-title":"N Engl J Med"},{"issue":"18","key":"2357_CR15","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1056\/NEJMoa2511774","volume":"393","author":"S Wharton","year":"2025","unstructured":"Wharton S, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025;393(18):1796\u2013806.","journal-title":"N Engl J Med"},{"issue":"4","key":"2357_CR16","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","volume":"87","author":"JJ Holst","year":"2007","unstructured":"Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409\u201339.","journal-title":"Physiol Rev"},{"issue":"1","key":"2357_CR17","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9(1):234.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2357_CR18","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.clinthera.2024.11.005","volume":"47","author":"M Marassi","year":"2025","unstructured":"Marassi M, Fadini GP. Real-world evidence on oral semaglutide for the management of type 2 diabetes. A narrative review for clinical practice. Clin Ther. 2025;47(1):102\u201310.","journal-title":"Clin Ther"},{"issue":"11","key":"2357_CR19","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1056\/NEJMoa2505669","volume":"393","author":"J Rosenstock","year":"2025","unstructured":"Rosenstock J, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. N Engl J Med. 2025;393(11):1065\u201376.","journal-title":"N Engl J Med"},{"issue":"10400","key":"2357_CR20","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S0140-6736(23)01302-8","volume":"402","author":"JP Frias","year":"2023","unstructured":"Frias JP, et al. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet. 2023;402(10400):472\u201383.","journal-title":"Lancet"},{"issue":"1","key":"2357_CR21","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s12933-025-02781-x","volume":"24","author":"S Wharton","year":"2025","unstructured":"Wharton S, et al. Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes. Cardiovasc Diabetol. 2025;24(1):240.","journal-title":"Cardiovasc Diabetol"},{"key":"2357_CR22","unstructured":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants With Established Atherosclerotic Cardiovascular Disease and\/or Chronic Kidney Disease. 2025."},{"issue":"13","key":"2357_CR23","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017;377(13):1228\u201339.","journal-title":"N Engl J Med"},{"issue":"23","key":"2357_CR24","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015;373(23):2247\u201357.","journal-title":"N Engl J Med"},{"issue":"2","key":"2357_CR25","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391(2):109\u201321.","journal-title":"N Engl J Med"},{"issue":"10313","key":"2357_CR26","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","volume":"398","author":"S Del Prato","year":"2021","unstructured":"Del Prato S, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811\u201324.","journal-title":"Lancet"},{"issue":"Supplement1","key":"2357_CR27","first-page":"S181","volume":"48","author":"ADAPP Committee","year":"2024","unstructured":"Committee ADAPP. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes\u20142025. Diabetes Care. 2024;48(Supplement1):S181\u2013206.","journal-title":"Diabetes Care"},{"issue":"4","key":"2357_CR28","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1093\/cvr\/cvac112","volume":"119","author":"S Madsbad","year":"2023","unstructured":"Madsbad S, Holst JJ. Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists. Cardiovasc Res. 2023;119(4):886\u2013904.","journal-title":"Cardiovasc Res"},{"issue":"17","key":"2357_CR29","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1161\/CIR.0000000000000920","volume":"142","author":"J Rangaswami","year":"2020","unstructured":"Rangaswami J, et al. Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association. Circulation. 2020;142(17):e265\u201386.","journal-title":"Circulation"},{"issue":"2","key":"2357_CR30","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255\u2013323.","journal-title":"Eur Heart J"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-026-02357-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-026-02357-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-026-02357-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:41:48Z","timestamp":1781642508000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-026-02357-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2357"],"URL":"https:\/\/doi.org\/10.1007\/s11886-026-02357-5","relation":{},"ISSN":["1534-3170"],"issn-type":[{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"5 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}